10.1002/tox.23487 144 ZhangL.LiC.ZhangY.ZhangJ.YangX
It has shown remarkable effectiveness in managing type 2 diabetes and has gained popularity due to its positive clinical trial results
GLP 1 Drug Biosimilar Market Size, Share & Trends Analysis by Reference Biologic (Semaglutide Biosimilar, Liraglutide Biosimilar, Exenatide Biosimilar, Dulaglutide Biosimilar), by Formulation (Injectable Pen, Oral Tablet, Patch & Implant), by Distribution (Retail Pharmacy, Mail-Order & Specialty Pharmacy, Hospital & Clinic), and Segment Forecasts, 2026 to 2035 GLP-1 biosimilars are biological medicines developed to be highly similar in quality, safety, and efficacy to the originator GLP-1 receptor agonists, such as semaglutide, liraglutide, and dulaglutide
Both are administered by licensed NPs and RNs via intramuscular injection for near-100% absorption, bypassing the digestive system entirely
Around 86% of participants in the semaglutide group reported an adverse event, compared to about 80% in the placebo group
When used in conjunction with diet and exercise, it can cause significant weight loss and a reduced risk of cancer, diabetes and heart disease -- in people who are obese or overweight
